Role of the Renin Angiotensin System in Diabetic Nephropathy

Overview

Journal World J Diabetes

Publisher Baishideng Publishing Group

Specialty Endocrinology

Date 2011 May 4

PMID 21537441

Citations 46

Authors

Tanuj Chawla

Deepika Sharma

Archana Singh

Affiliations

Soon will be listed here.

Abstract

Diabetic nephropathy has been the cause of lot of morbidity and mortality in the diabetic population. The renin angiotensin system (RAS) is considered to be involved in most of the pathological processes that result in diabetic nephropathy. This system has various subsystems which contribute to the disease pathology. One of these involves angiotensin II (Ang II) which shows increased activity during diabetic nephropathy. This causes hypertrophy of various renal cells and has a pressor effect on arteriolar smooth muscle resulting in increased vascular pressure. Ang II also induces inflammation, apoptosis, cell growth, migration and differentiation. Monocyte chemoattractant protein-1 production responsible for renal fibrosis is also regulated by RAS. Polymorphism of angiotensin converting enzyme (ACE) and Angiotensinogen has been shown to have effects on RAS. Available treatment modalities have proven effective in controlling the progression of nephropathy. Various drugs (based on antagonism of RAS) are currently in the market and others are still under trial. Amongst the approved drugs, ACE inhibitors and angiotensin receptor blockers (ARBs) are widely used in clinical practice. ARBs are shown to be superior to ACE inhibitors in terms of reducing proteinuria but the combined role of ARBs with ACE inhibitors in diabetic nephropathy is under debate.

Citing Articles

The effectiveness of antioxidant agents in delaying progression of diabetic nephropathy: A systematic review of randomized controlled trials.

Rahayu I, Arfian N, Kustanti C, Wahyuningsih M Bioimpacts. 2025; 15:30129.

PMID: 39963561 PMC: 11830129. DOI: 10.34172/bi.30129.

Pathophysiology and Advances in the Therapy of Cardiomyopathy in Patients with Diabetes Mellitus.

Graczyk P, Dach A, Dyrka K, Pawlik A Int J Mol Sci. 2024; 25(9).

PMID: 38732253 PMC: 11084712. DOI: 10.3390/ijms25095027.

Counter-regulatory RAS peptides: new therapy targets for inflammation and fibrotic diseases?.

Avila-Martinez D, Mixtega-Ruiz W, Hurtado-Capetillo J, Lopez-Franco O, Flores-Munoz M Front Pharmacol. 2024; 15:1377113.

PMID: 38666016 PMC: 11044688. DOI: 10.3389/fphar.2024.1377113.

The Role of Autophagy in Type 2 Diabetic Kidney Disease Management.

Tseng C, Shah K, Chiu I, Hsiao L Cells. 2023; 12(23).

PMID: 38067119 PMC: 10705810. DOI: 10.3390/cells12232691.

Role and mechanisms of SGLT-2 inhibitors in the treatment of diabetic kidney disease.

Dai Z, Chen J, Zou R, Liang X, Tang J, Yao C Front Immunol. 2023; 14:1213473.

PMID: 37809091 PMC: 10552262. DOI: 10.3389/fimmu.2023.1213473.

References

Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F . An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest. 1990; 86(4):1343-6. PMC: 296868. DOI: 10.1172/JCI114844. View

Rossing K, Jacobsen P, Pietraszek L, Parving H . Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial. Diabetes Care. 2003; 26(8):2268-74. DOI: 10.2337/diacare.26.8.2268. View

Jacobsen P, Rossing K, Parving H . Single versus dual blockade of the renin-angiotensin system (angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers) in diabetic nephropathy. Curr Opin Nephrol Hypertens. 2004; 13(3):319-24. DOI: 10.1097/00041552-200405000-00009. View

Freire M, Ji L, Onuma T, Orban T, Warram J, Krolewski A . Gender-specific association of M235T polymorphism in angiotensinogen gene and diabetic nephropathy in NIDDM. Hypertension. 1998; 31(4):896-9. DOI: 10.1161/01.hyp.31.4.896. View

Unger T, Dahlof B . Compound 21, the first orally active, selective agonist of the angiotensin type 2 receptor (AT2): implications for AT2 receptor research and therapeutic potential. J Renin Angiotensin Aldosterone Syst. 2009; 11(1):75-7. DOI: 10.1177/1470320309347792. View

Barnett A . Preventing renal complications in diabetic patients: the Diabetics Exposed to Telmisartan And enalaprIL (DETAIL) study. Acta Diabetol. 2005; 42 Suppl 1:S42-9. DOI: 10.1007/s00592-005-0180-4. View

Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N . A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res. 2000; 87(5):E1-9. DOI: 10.1161/01.res.87.5.e1. View

Borch-Johnsen K, Kreiner S . Proteinuria: value as predictor of cardiovascular mortality in insulin dependent diabetes mellitus. Br Med J (Clin Res Ed). 1987; 294(6588):1651-4. PMC: 1246824. DOI: 10.1136/bmj.294.6588.1651. View

Ozono R, Wang Z, Moore A, Inagami T, Siragy H, Carey R . Expression of the subtype 2 angiotensin (AT2) receptor protein in rat kidney. Hypertension. 1997; 30(5):1238-46. DOI: 10.1161/01.hyp.30.5.1238. View

10.

Ziyadeh F . Renal tubular basement membrane and collagen type IV in diabetes mellitus. Kidney Int. 1993; 43(1):114-20. DOI: 10.1038/ki.1993.19. View

11.

Rodriguez-Iturbe B, Pons H, Herrera-Acosta J, Johnson R . Role of immunocompetent cells in nonimmune renal diseases. Kidney Int. 2001; 59(5):1626-40. DOI: 10.1046/j.1523-1755.2001.0590051626.x. View

12.

Gerstein H, Mann J, Yi Q, Zinman B, Dinneen S, Hoogwerf B . Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA. 2001; 286(4):421-6. DOI: 10.1001/jama.286.4.421. View

13.

Cotter J, Oliveira P, Cunha P, Polonia J . Different patterns of one-year evolution of microalbuminuria in hypertensive patients treated with different inhibitors of the renin-angiotensin system. Rev Port Cardiol. 2009; 27(11):1395-404. View

14.

Siragy H, Inagami T, Carey R . NO and cGMP mediate angiotensin AT2 receptor-induced renal renin inhibition in young rats. Am J Physiol Regul Integr Comp Physiol. 2007; 293(4):R1461-7. DOI: 10.1152/ajpregu.00014.2007. View

15.

Ruiz-Ortega M, Lorenzo O, Ruperez M, Esteban V, Mezzano S, Egido J . Renin-angiotensin system and renal damage: emerging data on angiotensin II as a proinflammatory mediator. Contrib Nephrol. 2001; (135):123-37. DOI: 10.1159/000060153. View

16.

Doria A, Onuma T, Gearin G, Freire M, Warram J, Krolewski A . Angiotensinogen polymorphism M235T, hypertension, and nephropathy in insulin-dependent diabetes. Hypertension. 1996; 27(5):1134-9. DOI: 10.1161/01.hyp.27.5.1134. View

17.

Kambayashi Y, Nagata K, Ichiki T, Inagami T . Insulin and insulin-like growth factors induce expression of angiotensin type-2 receptor in vascular-smooth-muscle cells. Eur J Biochem. 1996; 239(3):558-65. DOI: 10.1111/j.1432-1033.1996.0558u.x. View

18.

Siragy H, Inagami T, Ichiki T, Carey R . Sustained hypersensitivity to angiotensin II and its mechanism in mice lacking the subtype-2 (AT2) angiotensin receptor. Proc Natl Acad Sci U S A. 1999; 96(11):6506-10. PMC: 26912. DOI: 10.1073/pnas.96.11.6506. View

19.

Ruggenenti P, Bettinaglio P, Pinares F, Remuzzi G . Angiotensin converting enzyme insertion/deletion polymorphism and renoprotection in diabetic and nondiabetic nephropathies. Clin J Am Soc Nephrol. 2008; 3(5):1511-25. PMC: 4571148. DOI: 10.2215/CJN.04140907. View

20.

Zoja C, Donadelli R, Colleoni S, Figliuzzi M, Bonazzola S, Morigi M . Protein overload stimulates RANTES production by proximal tubular cells depending on NF-kappa B activation. Kidney Int. 1998; 53(6):1608-15. DOI: 10.1046/j.1523-1755.1998.00905.x. View